MX2021002521A - Dimetilaminoazetidinaminas como inhibidores de jak. - Google Patents

Dimetilaminoazetidinaminas como inhibidores de jak.

Info

Publication number
MX2021002521A
MX2021002521A MX2021002521A MX2021002521A MX2021002521A MX 2021002521 A MX2021002521 A MX 2021002521A MX 2021002521 A MX2021002521 A MX 2021002521A MX 2021002521 A MX2021002521 A MX 2021002521A MX 2021002521 A MX2021002521 A MX 2021002521A
Authority
MX
Mexico
Prior art keywords
dimethylaminoazetidynamines
compounds
jak inhibitors
inhibitors
formula
Prior art date
Application number
MX2021002521A
Other languages
English (en)
Spanish (es)
Inventor
Daniel D Long
Cameron Smith
Corbin Thompson
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2021002521A publication Critical patent/MX2021002521A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021002521A 2018-09-04 2019-09-03 Dimetilaminoazetidinaminas como inhibidores de jak. MX2021002521A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726562P 2018-09-04 2018-09-04
PCT/US2019/049276 WO2020051105A1 (en) 2018-09-04 2019-09-03 Dimethyl amino azetidine amides as jak inhibitors

Publications (1)

Publication Number Publication Date
MX2021002521A true MX2021002521A (es) 2021-04-28

Family

ID=67982186

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002521A MX2021002521A (es) 2018-09-04 2019-09-03 Dimetilaminoazetidinaminas como inhibidores de jak.

Country Status (27)

Country Link
US (4) US10947229B2 (cg-RX-API-DMAC7.html)
EP (1) EP3837258B1 (cg-RX-API-DMAC7.html)
JP (2) JP7324836B2 (cg-RX-API-DMAC7.html)
KR (1) KR102826491B1 (cg-RX-API-DMAC7.html)
CN (1) CN112739697B (cg-RX-API-DMAC7.html)
AR (1) AR116115A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019336167B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004052A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021000514A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021002977A2 (cg-RX-API-DMAC7.html)
DK (1) DK3837258T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190681A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982858T3 (cg-RX-API-DMAC7.html)
FI (1) FI3837258T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241002T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068058T2 (cg-RX-API-DMAC7.html)
IL (1) IL281146B2 (cg-RX-API-DMAC7.html)
LT (1) LT3837258T (cg-RX-API-DMAC7.html)
MA (1) MA53229A (cg-RX-API-DMAC7.html)
MX (1) MX2021002521A (cg-RX-API-DMAC7.html)
PH (1) PH12021550368A1 (cg-RX-API-DMAC7.html)
PL (1) PL3837258T3 (cg-RX-API-DMAC7.html)
PT (1) PT3837258T (cg-RX-API-DMAC7.html)
SG (1) SG11202101734RA (cg-RX-API-DMAC7.html)
SI (1) SI3837258T1 (cg-RX-API-DMAC7.html)
TW (1) TWI791886B (cg-RX-API-DMAC7.html)
WO (1) WO2020051105A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ip有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
TWI754019B (zh) 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
BR112021004063A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
BR112021004087A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc processo para preparar inibidores de jak e seus intermediários
DK3837258T3 (da) * 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
KR20220149585A (ko) 2020-03-02 2022-11-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제 화합물의 결정성 수화물
TW202207921A (zh) * 2020-05-08 2022-03-01 美商施萬生物製藥研發Ip有限責任公司 以二甲基胺基吖呾醯胺化合物治療受冠狀病毒感染的患者之方法
WO2022271604A1 (en) 2021-06-21 2022-12-29 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
TW202317550A (zh) * 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
CN118401508A (zh) * 2021-12-17 2024-07-26 株式会社大熊制药 (2R,3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新酸加成盐及晶形
CN119403552A (zh) 2022-05-05 2025-02-07 施万生物制药研发Ip有限责任公司 用于通过雾化口腔吸入递送的奈珠西替尼
WO2023230236A1 (en) 2022-05-26 2023-11-30 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
CA2756989A1 (en) 2009-04-03 2010-10-07 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
EP3831830A1 (en) 2015-11-03 2021-06-09 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ip有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
DK3712152T3 (da) 2015-11-03 2021-03-22 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
US20180258546A1 (en) 2017-03-09 2018-09-13 Lam Research Corporation Electroplating apparatus and methods utilizing independent control of impinging electrolyte
TWI754019B (zh) 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
EP3619208B1 (en) 2017-05-01 2023-06-07 Theravance Biopharma R&D IP, LLC Crystalline forms of a jak inhibitor compound
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
US11878270B2 (en) 2018-07-20 2024-01-23 Porifera, Inc. Osmosis modules having recirculation loops
BR112021004087A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc processo para preparar inibidores de jak e seus intermediários
DK3837258T3 (da) * 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
BR112021004063A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
EP3853229A1 (en) 2018-10-29 2021-07-28 Theravance Biopharma R&D IP, LLC 2-azabicyclo hexane compound as jak inhibitor
KR102873783B1 (ko) 2019-02-25 2025-10-21 메디노 파마슈티컬 테크놀로지 (주하이) 컴퍼니 리미티드 Jak 억제제 화합물 및 그 사용
UA130579C2 (uk) 2019-03-05 2026-03-25 Інсайт Корпорейшн Інгібітори шляхів jak1 для лікування хронічної дисфункції алотрансплантата легень
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途
KR20220149585A (ko) * 2020-03-02 2022-11-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제 화합물의 결정성 수화물
TW202207921A (zh) 2020-05-08 2022-03-01 美商施萬生物製藥研發Ip有限責任公司 以二甲基胺基吖呾醯胺化合物治療受冠狀病毒感染的患者之方法
WO2022178215A1 (en) 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
CA3212635A1 (en) 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound
WO2022271604A1 (en) * 2021-06-21 2022-12-29 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l

Also Published As

Publication number Publication date
US20250034131A1 (en) 2025-01-30
JP7324836B2 (ja) 2023-08-10
AU2019336167A1 (en) 2021-03-11
JP2021535177A (ja) 2021-12-16
AU2019336167B2 (en) 2024-08-29
SI3837258T1 (sl) 2024-09-30
HUE068058T2 (hu) 2024-12-28
WO2020051105A1 (en) 2020-03-12
EP3837258B1 (en) 2024-04-24
PT3837258T (pt) 2024-06-20
CL2021000514A1 (es) 2021-07-23
US12398135B2 (en) 2025-08-26
HRP20241002T1 (hr) 2024-10-25
TWI791886B (zh) 2023-02-11
IL281146B2 (en) 2023-12-01
IL281146B1 (en) 2023-08-01
US20230322774A1 (en) 2023-10-12
LT3837258T (lt) 2024-05-27
PL3837258T3 (pl) 2024-09-16
CN112739697B (zh) 2023-10-20
AR116115A1 (es) 2021-03-31
KR102826491B1 (ko) 2025-06-27
US20210155620A1 (en) 2021-05-27
ES2982858T3 (es) 2024-10-17
EA202190681A1 (ru) 2021-05-28
KR20210056381A (ko) 2021-05-18
JP2022172299A (ja) 2022-11-15
BR112021004052A2 (pt) 2021-05-25
MA53229A (fr) 2022-05-11
SG11202101734RA (en) 2021-03-30
CN112739697A (zh) 2021-04-30
CO2021002977A2 (es) 2021-05-31
DK3837258T3 (da) 2024-07-22
EP3837258A1 (en) 2021-06-23
TW202024073A (zh) 2020-07-01
IL281146A (en) 2021-04-29
FI3837258T3 (fi) 2024-05-27
PH12021550368A1 (en) 2022-03-28
US20200071323A1 (en) 2020-03-05
US10947229B2 (en) 2021-03-16
US11634419B2 (en) 2023-04-25

Similar Documents

Publication Publication Date Title
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CL2018001145A1 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
MX2019010541A (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
CL2019002204A1 (es) Compuestos inhibidores del vih.
MX2018015625A (es) Compuestos y composiciones para inhibir la actividad de shp2.
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
CL2020001090A1 (es) Compuesto de pirimidina como inhibidor de las janocinasas.
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
BR112018071585A2 (pt) formulações de um inibidor de lsd1
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201791576A1 (ru) Ингибитор jak
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
JOP20210127A1 (ar) مركبات عطرية غير متجانسة كمثبطات Vanin
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
BR112021011325A2 (pt) Derivados de rapamicina
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
EA201990686A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы